This article is more than 5 years old. Information may no longer be current.

FDA approves Lotemax gel for postop inflammation and pain

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has approved Lotemax gel drop formulation for the treatment of inflammation and pain after ocular surgery, according to a news release.

Lotemax (loteprednol etabonate ophthalmic gel 0.5%, Bausch + Lomb) is a topical corticosteroid formulation in the company’s line of loteprednol ophthalmic products.

One or two drops of Lotemax gel are applied into the conjunctival sac of the affected eye four times each day for 2 weeks after surgery. As with other corticosteroids, it is contraindicated in most viral diseases of the conjunctiva and cornea, the release said.

Adverse reactions related to Lotemax gel include anterior chamber inflammation in 5% of cases, foreign body sensation in 2% of cases and eye pain in 2% of cases, according to the release.